

# ASX Market Announcement



## GTG COVID-19 Risk Test launch update

**Melbourne, Australia, 9 April 2021:** Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company", "GTG"), a diversified Genomics and AI driven preventative health business provides an update to the market on the progress of the US commercial availability of the Company's COVID-19 Serious Disease Risk Test ('COVID-19 Risk Test') via US Based Infinity BiologiX LLC ('IBX'), (ref: ASX Announcement 3 March 2021).

Genetic Technologies advises that the Company has completed all validation and data-based analysis for the COVID-19 Risk Test. IBX, our US based distribution partner is currently completing the technical interface with their telehealth partner for the commercial availability of the COVID-19 Risk Test across the United States.

The technical interface is a requirement for the submission to Centres for Medicare and Medicaid Services ('CMS'), with submission required prior to the commercial release of the COVID-19 Risk Test by IBX.

Further updates will be provided in due course.

-END-

Authorised by the Board of Genetic Technologies

**Investor Relations (AUS)**

Stephanie Ottens

Market Eye

M: +61 434 405 400

E: [stephanie.ottens@marketeye.com.au](mailto:stephanie.ottens@marketeye.com.au)**Investor Relations and Media (US)**

Dave Gentry

1 800 RED CHIP (733 2447)

Cell: 407 491 4498

E: [dave@redchip.com](mailto:dave@redchip.com)**About Genetic Technologies Limited**

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company's lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products.

For more information, please visit [www.gtglabs.com](http://www.gtglabs.com)

**About Infinity BiologiX:**

Infinity BiologiX (IBX) is a market-disrupting next-generation central laboratory supporting academia, government, and industry. IBX provides global sample collection, processing, storage, and analytical services integrated with scientific and technical support in both the research and clinical arenas. As a leader in biomaterials, IBX provides support to the development of diagnostics, therapeutics, and research in the genomics, precision, and regenerative medicine arenas. IBX previously operated as RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020

For more information, visit [www.ibx.bio](http://www.ibx.bio)